DOCK1 and neoplasm: Mechanistically, metformin facilitates the activation of RAC1 by phosphorylating DOCK1 (Fig. 3D, 3H and 3J), which in turn attenuates the anti-tumor effects of metformin, leading to the observed unresponsiveness in liver cancer.